Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The emergence of follow-on disease-modifying therapies for multiple sclerosis.

Moss BP, Cohen JA.

Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106. [Epub ahead of print]

PMID:
31074707
2.

Wellness and the Role of Comorbidities in Multiple Sclerosis.

Moss BP, Rensel MR, Hersh CM.

Neurotherapeutics. 2017 Oct;14(4):999-1017. doi: 10.1007/s13311-017-0563-6. Review.

3.

Neurosarcoidosis.

Culver DA, Ribeiro Neto ML, Moss BP, Willis MA.

Semin Respir Crit Care Med. 2017 Aug;38(4):499-513. doi: 10.1055/s-0037-1604165. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750463
4.

Safety of monoclonal antibodies for the treatment of multiple sclerosis.

McGinley MP, Moss BP, Cohen JA.

Expert Opin Drug Saf. 2017 Jan;16(1):89-100. Epub 2016 Oct 31. Review.

PMID:
27756172

Supplemental Content

Support Center